C. Pétorin

发表

Colorectal Cancer Survivors Suffering From Sensory Chemotherapy-Induced Peripheral Neuropathy Are Not a Homogenous Group: Secondary Analysis of Patients’ Profiles With Oxaliplatin-Induced Peripheral Neuropathy

C. Lambert, S. Melnikov, O. Bouché, 2021, Frontiers in Pharmacology.

Randomized Phase II Trial Evaluating Two Sequential Treatments in First Line of Metastatic Pancreatic Cancer: Results of the PANOPTIMOX-PRODIGE 35 Trial

C. Lepage, O. Bouché, C. Pétorin, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prevention of oxaliplatin-induced peripheral neuropathy by a polyamine-reduced diet—NEUROXAPOL: protocol of a prospective, randomised, controlled, single-blind and monocentric trial

A. Eschalier, C. Pétorin, D. Pezet, 2015, BMJ Open.

Lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours: An international double-blind, placebo-controlled randomised phase II trial - Prodige 31 REMINET: An FFCD study.

A. Lièvre, C. Lepage, C. Lombard-Bohas, 2022, European journal of cancer.

Effect of prehabilitation in gastro-oesophageal adenocarcinoma: study protocol of a multicentric, randomised, control trial—the PREHAB study

K. Slim, F. Costes, C. Mariette, 2016, BMJ Open.

1163P Lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours (NETs): An international double-blind, placebo-controlled randomized phase II trial

A. Lièvre, C. Lepage, J. Scoazec, 2020 .

The Value of Clonality in the Diagnosis and Follow-up of Patients With Cutaneous T-cell Infiltrates

L. Gaboury, C. Pétorin, C. Séguin, 2001, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

Prognostic factors of metastatic neuroendocrine carcinoma under first-line treatment with platinum etoposide with a focus on NEC score and Rb expression: Results from the multicentre RBNEC study of the Groupe d'Etude des Tumeurs Endocrines (GTE) and the ENDOCAN-RENATEN network.

M. Ducreux, E. Baudin, V. Hervieu, 2021, European journal of cancer.

ONCOGRAM: study protocol for the evaluation of therapeutic response and survival of metastatic colorectal cancer patients treated according to the guidelines of a chemosensitivity assay, the Oncogramme®

B. Chauffert, Y. Bécouarn, M. Pradel, 2021, Trials.

Long-Term Prevalence of Sensory Chemotherapy-Induced Peripheral Neuropathy for 5 Years after Adjuvant FOLFOX Chemotherapy to Treat Colorectal Cancer: A Multicenter Cross-Sectional Study

O. Bouché, N. Kerckhove, M. Selvy, 2020, Journal of clinical medicine.

Everolimus after hepatic arterial embolisation therapy of metastases from gastrointestinal neuroendocrine tumours: The FFCD 1104-EVACEL-GTE phase II study.

T. de Baère, E. Baudin, C. Lepage, 2019, European journal of cancer.

Second-line treatment and prognostic factors in neuroendocrine carcinoma.

E. Baudin, V. Hervieu, J. Scoazec, 2022, Endocrine-Related Cancer.

Assessment of the Relation between the Expression of Oxaliplatin Transporters in Colorectal Cancer and Response to FOLFOX-4 Adjuvant Chemotherapy: A Case Control Study

C. Pétorin, D. Pezet, D. Balayssac, 2016, PloS one.

Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial

Joon-Oh Park, H. Harputluoglu, G. Brandi, 2023, The Lancet.

FOLFIRINOX until progression, FOLFIRINOX with maintenance treatment, or sequential treatment with gemcitabine and FOLFIRI.3 for first-line treatment of metastatic pancreatic cancer: A randomized phase II trial (PRODIGE 35-PANOPTIMOX).

C. Lepage, C. Pétorin, J. Seitz, 2018 .

The prognostic influence of the proliferative discordance in metastatic pancreatic neuroendocrine carcinoma revealed by peptide receptor radionuclide therapy

C. Pétorin, A. Kelly, S. Maqdasy, 2017, Medicine.

Poorly differentiated gastro-entero-pancreatic neuroendocrine carcinomas: Are they really heterogeneous? Insights from the FFCD-GTE national cohort.

E. Baudin, C. Lepage, P. Rougier, 2017, European journal of cancer.

Satisfaction of Cancer Patients Treated with Oral Anticancer Medications regarding Dispensing by Community Pharmacists: A Cross-Sectional Study

J. Bay, C. Pétorin, D. Balayssac, 2023, European Journal of Cancer Care.

PROPERTY: study protocol for a randomized, double-blind, multicenter placebo-controlled trial assessing neurotoxicity in patients with metastatic gastrointestinal cancer taking PHYCOCARE® during oxaliplatin-based chemotherapy

C. Volteau, Y. Péréon, C. Pétorin, 2023, Trials.

Motor disorders related to oxaliplatin-induced peripheral neuropathy: long-term severity and impact on quality of life.

N. Kerckhove, M. Selvy, Coralie Gonneau, 2024, Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer.

Neoadjuvant radiotherapy combined with fluorouracil-cisplatin plus cetuximab in operable, locally advanced esophageal carcinoma: Results of a phase I-II trial (FFCD-0505/PRODIGE-3)

C. Lepage, C. Pétorin, T. Mazard, 2024, Clinical and translational radiation oncology.